Synthetic modeling reveals HOXB genes are critical for the initiation and maintenance of human leukemia

Mechanistic studies in human cancer have relied heavily on cell lines and mouse models, but are limited by in vitro adaptation and species context issues, respectively. More recent efforts have utilized patient-derived xenografts; however, these are hampered by variable genetic background, inability to study early events, and practical issues with availability/reproducibility. We report here an efficient, reproducible model of T-cell leukemia in which lentiviral transduction of normal human cord blood yields aggressive leukemia that appears indistinguishable from natural disease. We utilize this synthetic model to uncover a role for oncogene-induced HOXB activation which is operative in leukemia cells-of-origin and persists in established tumors where it defines a novel subset of patients distinct from other known genetic subtypes and with poor clinical outcome. We show further that anterior HOXB genes are specifically activated in human T-ALL by an epigenetic mechanism and confer growth advantage in both pre-leukemia cells and established clones.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code

Data collection
No software was used for data collection.

Data analysis
GraphPad Prism v8.0.1, ELDA tool (http://bioinf.wehi.edu.au/software/elda/) For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:   Figure 9 is available from the corresponding author upon reasonable request. All other data supporting the findings of this study are available within the article and its Supplementary Information files, or from the corresponding author upon reasonable request. A reporting summary for this article is available as a Supplementary Information file.

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
No sample-size calculation was performed. Sample sizes were chosen to be as large as possible given resource constraints. The sample sizes were deemed sufficient to support conclusions if statistical signficance was met. If the sample sizes were insufficient to support drawing of conclusions, then no conclusions were made.
Data exclusions No data were excluded from analysis.

Replication
Experiments were replicated as indicated in the associated figure legends and/or manuscript text.
Randomization Samples were not randomly allocated into experimental groups. Co-variates were controlled by performing isogenic comparisons.

Blinding
Blinding is not relevant to the current study as samples were not randomly allocated to subgroups for analysis.

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Validation
All antibodies were validated by the supplier for human samples. Mycoplasma contamination All cell lines tested negative for mycoplasma contamination (MycoAlert detection kit; Lonza).

Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Wild animals
The study did not involve wild animals.

Field-collected samples
The study did not involve samples collected from the field.

Ethics oversight
Research Note that full information on the approval of the study protocol must also be provided in the manuscript.

ChIP-seq Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

Data access links
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.

Methodology
Sample preparation Live single cell suspensions obtained from bone marrow or spleen of leukemic mice, or live single cell suspensions from tissue culture, filtered through 70um nylon mesh.

Instrument BD LSR-Fortessa, FACSCalibur
Software FlowJo Cell population abundance CD34+ CB cells were FACS sorted to 95-99% purity as assessed by post-sort analysis on the same instrument. G+C+, G+C-, and G-C-populations from transduced CB cells or primary CB leukemias were FACS sorted to >95% purity as assessed by post-sort analysis on the same instrument. G+C+N+ cells sorted at limiting dilution into 96-well plates for the well-initiation assay (Fig 8e/f) could not be assessed for purity after sorting; however, ~90% of assayable wells after 3 weeks' culture were populated by G+C+N + cells.